QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)

Eli Lilly and (LLY) Competitors

$445.64
+9.27 (+2.12%)
(As of 06/8/2023 ET)
Compare
Today's Range
$432.34
$447.46
50-Day Range
$340.69
$444.26
52-Week Range
$283.11
$454.95
Volume
2.04 million shs
Average Volume
3.14 million shs
Market Capitalization
$423.03 billion
P/E Ratio
70.85
Dividend Yield
1.01%
Price Target
$425.05

LLY vs. JNJ, MRK, PFE, BMY, NVO, AZN, NVS, ABT, SNY, and UNH

Should you be buying Eli Lilly and stock or one of its competitors? The main competitors of Eli Lilly and include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Novartis (NVS), Abbott Laboratories (ABT), Sanofi (SNY), and UnitedHealth Group (UNH). These companies are all part of the "medical" sector.

Eli Lilly and vs.

Eli Lilly and (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, community ranking, valuation and earnings.

Eli Lilly and pays an annual dividend of $4.52 per share and has a dividend yield of 1.0%. Johnson & Johnson pays an annual dividend of $4.76 per share and has a dividend yield of 3.0%. Eli Lilly and pays out 71.9% of its earnings in the form of a dividend. Johnson & Johnson pays out 99.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

In the previous week, Johnson & Johnson had 7 more articles in the media than Eli Lilly and. MarketBeat recorded 23 mentions for Johnson & Johnson and 16 mentions for Eli Lilly and. Eli Lilly and's average media sentiment score of 0.31 beat Johnson & Johnson's score of 0.11 indicating that Eli Lilly and is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eli Lilly and
5 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
Johnson & Johnson
9 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
4 Very Negative mention(s)
Neutral

Eli Lilly and has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Johnson & Johnson has higher revenue and earnings than Eli Lilly and. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and$28.54 billion14.78$6.24 billion$6.2970.63
Johnson & Johnson$94.94 billion4.35$17.94 billion$4.7833.25

82.1% of Eli Lilly and shares are held by institutional investors. Comparatively, 67.9% of Johnson & Johnson shares are held by institutional investors. 0.1% of Eli Lilly and shares are held by insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Eli Lilly and has a net margin of 20.54% compared to Johnson & Johnson's net margin of 13.22%. Eli Lilly and's return on equity of 61.42% beat Johnson & Johnson's return on equity.

Company Net Margins Return on Equity Return on Assets
Eli Lilly and 20.54% 61.42% 12.74%
Johnson & Johnson 13.22% 36.13% 14.66%

Eli Lilly and currently has a consensus target price of $425.05, suggesting a potential downside of 4.22%. Johnson & Johnson has a consensus target price of $171.57, suggesting a potential upside of 8.08%. Given Johnson & Johnson's higher possible upside, analysts clearly believe Johnson & Johnson is more favorable than Eli Lilly and.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eli Lilly and
1 Sell rating(s)
2 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.73
Johnson & Johnson
0 Sell rating(s)
7 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.46

Eli Lilly and received 79 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 70.51% of users gave Eli Lilly and an outperform vote while only 64.87% of users gave Johnson & Johnson an outperform vote.

CompanyUnderperformOutperform
Eli Lilly andOutperform Votes
1124
70.51%
Underperform Votes
470
29.49%
Johnson & JohnsonOutperform Votes
1045
64.87%
Underperform Votes
566
35.13%

Summary

Eli Lilly and beats Johnson & Johnson on 12 of the 20 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LLY vs. The Competition

MetricEli Lilly andPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$421.73B$5.93B$4.57B$14.94B
Dividend Yield1.02%2.59%2.37%3.93%
P/E Ratio70.634.2590.1518.73
Price / Sales14.78330.433,428.788.93
Price / Cash48.3420.7191.0623.78
Price / Book39.184.784.707.32
Net Income$6.24B$191.04M$117.69M$899.92M
7 Day Performance1.79%2.32%2.47%5.08%
1 Month Performance2.67%0.99%1.80%4.70%
1 Year Performance41.72%14.38%10.97%-6.39%

Eli Lilly and Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JNJ
Johnson & Johnson
2.3509 of 5 stars
$158.19
-0.1%
$171.57
+8.5%
-11.1%$411.09B$94.94B33.09155,800
MRK
Merck & Co., Inc.
2.8686 of 5 stars
$110.00
-2.7%
$120.75
+9.8%
+20.0%$279.12B$59.28B21.4869,000
PFE
Pfizer
3.0583 of 5 stars
$38.37
-0.7%
$47.33
+23.4%
-27.9%$216.58B$92.95B7.5583,000
BMY
Bristol-Myers Squibb
2.3804 of 5 stars
$65.48
-0.8%
$78.62
+20.1%
-14.9%$137.56B$45.85B19.0934,300Analyst Revision
NVO
Novo Nordisk A/S
2.6529 of 5 stars
$160.71
+1.8%
$383.33
+138.5%
+36.0%$360.60B$25.06B42.2955,185
AZN
AstraZeneca
2.5663 of 5 stars
$73.40
+0.3%
$103.00
+40.3%
+11.8%$227.52B$44.35B48.2983,500Analyst Revision
NVS
Novartis
1.9342 of 5 stars
$99.68
+0.3%
$82.25
-17.5%
+10.8%$211.28B$50.55B30.67101,703
ABT
Abbott Laboratories
3.0176 of 5 stars
$102.66
-1.1%
$121.26
+18.1%
-13.0%$178.52B$41.51B31.20115,000
SNY
Sanofi
2.483 of 5 stars
$51.49
+1.3%
$94.50
+83.5%
-5.2%$129.85B$45.31B18.4691,573
UNH
UnitedHealth Group
3.1585 of 5 stars
$487.57
-2.1%
$599.06
+22.9%
-3.0%$453.94B$324.16B22.29400,000Dividend Increase
Analyst Upgrade

Related Companies and Tools

This page (NYSE:LLY) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -